Shotgun Metagenomics Clinical Reporting Market Global Report 2026

The shotgun metagenomics clinical reporting market size has grown rapidly in recent years. It will grow from $1.58 billion in 2025 to $1.83 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to advancement of next-generation sequencing technologies enabling clinical adoption, increasing prevalence of infectious disease outbreaks driving diagnostic demand, growth in microbiology and clinical genomics research funding, expansion of hospital laboratory molecular testing infrastructure, rising awareness of antimicrobial resistance monitoring needs.

The shotgun metagenomics clinical reporting market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to expansion of precision medicine and personalized diagnostics adoption, increasing integration of AI in genomic data interpretation, growth in decentralized and point-of-care sequencing systems, rising demand for rapid pathogen detection in critical care settings, expansion of cloud-based bioinformatics platforms for clinical workflows. Major trends in the forecast period include ai-driven pathogen detection and automated clinical interpretation systems, cloud-based genomic data sharing platforms for real-time diagnostics, ultra-rapid sequencing workflows for point-of-care infectious disease detection, integrated antimicrobial resistance prediction using genomic analytics, decentralized sequencing systems for hospital-based rapid metagenomic testing.

The increasing prevalence of infectious diseases is expected to drive the growth of the shotgun metagenomics clinical reporting market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can spread among individuals, animals, or through environmental sources. The prevalence of infectious diseases is rising due to the increasing occurrence of disease outbreaks linked to greater global connectivity and population movement. Shotgun metagenomics clinical reporting supports infectious disease management by enabling rapid and comprehensive detection of pathogens, antimicrobial resistance markers, and co-infections from clinical samples, helping healthcare providers achieve accurate diagnosis and targeted treatment. For instance, in October 2024, according to the World Health Organization, a Switzerland-based public health organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, compared to 7.5 million people in 2022, reflecting an increase of around 9.3%. Therefore, the increasing prevalence of infectious diseases is driving the growth of the shotgun metagenomics clinical reporting market.

Major companies operating in the shotgun metagenomics clinical reporting market are focusing on the development of advanced solutions, such as respiratory-focused genomic panels, to analyze microbial cell-free DNA from targeted clinical fluids and enhance diagnostic standards for vulnerable patient populations. Respiratory-focused genomic panels are specialized applications of metagenomic sequencing designed to identify and sequence fragmented pathogen DNA directly from complex, matrix-specific biological fluids, such as lung wash samples, enabling rapid, culture-independent diagnosis of complex respiratory tract infections. For instance, in April 2025, Karius Inc. launched Karius Focus BAL, a comprehensive metagenomic sequencing test that uses bronchoalveolar lavage fluid to analyze microbial cell-free DNA. The diagnostic solution evaluates fluid samples directly to identify more than 500 pathogens, provides processed diagnostic results within one calendar day of receiving samples, and detects 50% more causes of infectious pneumonia compared to conventional testing approaches.

In April 2026, Karius Inc., a US-based infectious disease diagnostics company, partnered with Mayo Clinic Laboratories to broaden access to advanced metagenomic infectious disease testing. Through this partnership, Karius aimed to make its Karius Spectrum and Karius Focus | BAL tests available for ordering through Mayo Clinic Laboratories, enabling improved access to comprehensive pathogen detection and clinical diagnostic reporting. Mayo Clinic Laboratories is a US-based clinical laboratory services provider specializing in advanced diagnostic testing and laboratory medicine.

Major companies operating in the shotgun metagenomics clinical reporting market report are BaseClear B.V., BGI Genomics Co. Ltd., BugSeq Bioinformatics Inc., CD Genomics Inc., Cmbio, Eurofins Scientific, Genome Detective, Illumina Inc., Karius Inc., Macrogen Inc., Microba Life Sciences Limited, Novogene Co. Ltd., Nucleome Informatics Private Limited, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Psomagen Inc., QIAGEN N.V., Revvity Inc., Strand Life Sciences Private Limited, Synnovis Group LLP, Takara Bio Inc., Thermo Fisher Scientific Inc., Yaazh Xenomics Private Limited, Zymo Research Corporation.

North America was the dominating region in the shotgun metagenomics clinical reporting market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the shotgun metagenomics clinical reporting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the shotgun metagenomics clinical reporting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.